RAMM PharmaXCNQ:RAMM Quick Ratio is 0.41 as of Jan. 2026, which is 89% below its 10-year median of 3.86. The stock has 4 warning signs investors should review. Among 996 Drug Manufacturers companies, RAMM Pharma ranks worse than 91.67% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. RAMM Pharma's quick ratio for the quarter that ended in Jan. 2026 was 0.41.
RAMM Pharma has a quick ratio of 0.41. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for RAMM Pharma's Quick Ratio or its related term are showing as below:
XCNQ:RAMM'
s Quick Ratio Range Over the Past 10 Years
Min: 0.41 Med: 3.86 Max: 22.27
Current: 0.41
During the past 8 years, RAMM Pharma's highest Quick Ratio was 22.27. The lowest was 0.41. And the median was 3.86.
XCNQ:RAMM's Quick Ratio is ranked worse than 91.67% of 996
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs XCNQ:RAMM: 0.41
RAMM Pharma (XCNQ:RAMM) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
RAMM Pharma Quick Ratio Related Terms
RAMM Pharma Quick Ratio Historical Data
* Premium members only.
The historical data trend for RAMM Pharma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, RAMM Pharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RAMM Pharma Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RAMM Pharma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where RAMM Pharma's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
RAMM Pharma's Quick Ratio for the fiscal year that ended in Oct. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RAMM Pharma (XCNQ:RAMM) has a Quick Ratio of 0.41 as of Jan. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on RAMM Pharma and its competitors. This is 89% below median its historical median of 3.86. Over the past decade, RAMM Pharma's Quick Ratio has ranged from 0.41 to 22.27. According to the industry distribution chart, RAMM Pharma ranks #913 out of 996 companies in the Drug Manufacturers industry, placing it in the top 91.7%.
Is RAMM Pharma's Quick Ratio too high?
RAMM Pharma's current Quick Ratio of 0.41 is 89% below median its 10-year median of 3.86. Over the past 10 years, this metric has ranged from a low of 0.41 to a high of 22.27. The Drug Manufacturers industry median Quick Ratio is 1.45. RAMM Pharma's value of 0.41 is 71.7% below this industry median. Based on the distribution chart, RAMM Pharma ranks #913 out of 996 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does RAMM Pharma's Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, RAMM Pharma ranks #913 out of 996 companies for Quick Ratio. This places RAMM Pharma in the lower half of its industry. The industry median Quick Ratio is 1.45. RAMM Pharma's value of 0.41 is 71.7% below this benchmark. Historically, RAMM Pharma's own Quick Ratio has ranged from 0.41 to 22.27 over the past decade. While the company's 10-year median is 3.86 vs. the industry median of 1.45, RAMM Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RAMM Pharma's current Quick Ratio of 0.41 is 71.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on RAMM Pharma and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RAMM Pharma's current Quick Ratio is 0.41, which is 89% below median its own 10-year median of 3.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RAMM Pharma stock overvalued right now?
Based on GuruFocus' analysis, RAMM Pharma (XCNQ:RAMM) is currently considered Fairly Valued. The stock's GF Value™ is C$0.01, compared to a current price of C$0.01 — trading right at its estimated fair value. The current Quick Ratio is 0.41, which is 89% below median its 10-year median of 3.86 and 71.7% below the Drug Manufacturers industry median of 1.45. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For RAMM Pharma (XCNQ:RAMM), the current Quick Ratio is 0.41 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RAMM Pharma Corp is engaged in the pharmaceutical and medical product business, including cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products. The group generates revenue from the sale of medical devices and consumables, the sale of pharmaceutical products, and sale of cosmetics. Geographically, it derives a majority of its revenue from Uruguay.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:RAMM has been successfully added to your 